

# THE LANCET

## Infectious Diseases

### Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; published online Feb 24. [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4).

**Table 1. Clinical characteristics and laboratory findings of patients with COVID-19 pneumonia**

Variable	Group 1 (n=15)	Group 2 (n=21)	Group 3 (n=30)	Group 4 (n=15)	All patients (n=81)	p value
Age (years)	44.9 ± 9.0	48.8 ± 13.0	52.3 ± 13.0	49.5 ± 11.0	49.5 ± 11.0	0.2778
>50	4 (26.7%) (7.8%, 55.1%)	10 (47.6%) (25.7%, 70.2%)	19 (63.3%) (43.9%, 80.1%)	7 (46.7%) (21.3%, 73.4%)	40 (49.4%) (38.1%, 60.7%)	0.1444
≤50	11 (73.3%) (44.9%, 92.2%)	11 (52.4%) (29.8%, 74.3%)	11 (36.7%) (19.9%, 56.1%)	8 (53.3%) (26.6%, 78.7%)	41 (50.6%) (39.3%, 61.9%)	
Sex						0.0871
Male	4 (26.7%) (7.8%, 55.1%)	11 (52.4%) (29.8%, 74.3%)	20 (66.7%) (47.2%, 82.7%)	7 (46.6%) (21.3%, 73.4%)	42 (51.9%) (40.5%, 63.1%)	
Female	11 (73.3%) (44.9%, 92.2%)	10 (47.6%) (25.7%, 70.2%)	10 (33.3%) (17.3%, 52.8%)	8 (53.3%) (26.6%, 78.7%)	39 (48.2%) (36.9%, 59.5%)	
History of exposure to Huanan market	0 (0.0%) (0.0%, 21.8%)	8 (38.1%) (18.1%, 61.6%)	14 (46.7%) (28.3%, 65.7%)	9 (60.0%) (32.3%, 83.7%)	31 (38.3%) (27.7%, 49.7%)	0.0013*
<b>Clinical symptoms</b>						
Fever	0 (0.0%) (0.0%, 21.8%)	18 (85.7%) (63.66%, 97.0%)	27 (90.0%) (73.47%, 97.9%)	14 (93.3%) (68.1%, 99.9%)	59 (72.9%) (61.8%, 82.1%)	<0.0001*
Maximal temperature, °C	36.6 ± 0.1	38.1 ± 0.8	38.2 ± 0.8	38.5 ± 0.7	37.9 ± 1.0	<0.0001*
≤37.3	15 (100%) (78.2%, 100%)	3 (14.3%) (3.1%, 36.3%)	5 (16.7%) (5.6%, 34.7%)	1 (6.7%) (0.2%, 32.0%)	24 (29.6%) (20.0%, 40.8%)	<0.0001*
37.3–38	0 (0%) (0.00%, 21.8%)	9 (42.9%) (21.8%, 66.0%)	8 (26.7%) (12.3%, 45.9%)	3 (20.0%) (4.3%, 48.1%)	20 (24.7%) (15.8%, 35.5%)	
38–39	0 (0%) (0.00%, 21.8%)	7 (33.3%) (14.6%, 57.0%)	11 (36.7%) (20.0%, 56.1%)	5 (33.3%) (11.8%, 61.6%)	23 (28.4%) (18.9%, 40.0%)	
>39	0 (0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	6 (20.0%) (7.7%, 38.6%)	6 (40.0%) (16.3%, 67.7%)	14 (17.3%) (9.8%, 27.3%)	
<b>Symptoms</b>						
Dyspnoea	0 (0.0%) (0.0%, 21.8%)	9 (42.9%) (21.8%, 66.0%)	13 (43.3%) (25.5%, 62.6%)	12 (80.0%) (51.9%, 95.7%)	34 (42.0%) (31.1%, 53.5%)	<0.0001*
Chest tightness	0 (0.0%) (0.0%, 21.8%)	5 (23.8%) (8.2%, 47.2%)	7 (23.3%) (9.9%, 42.3%)	6 (40.0%) (16.3%, 67.7%)	18 (22.2%) (13.7%, 32.8%)	0.0467
Cough	0 (0%) (0.0%, 21.8%)	15 (71.4%) (47.8%, 88.7%)	21 (70.0%) (50.6%, 85.3%)	12 (80.0%) (51.9%, 95.7%)	48 (59.3%) (47.8%, 70.1%)	<0.0001*
Sputum	0 (0.0%) (0.0%, 21.8%)	3 (14.3%) (3.1%, 36.3%)	6 (20.0%) (7.7%, 38.6%)	6 (40.0%) (16.3%, 67.7%)	15 (18.5%) (10.8%, 28.7%)	0.0385*

Rhinorrhoea	0 (0.0%) (0.0%, 21.8%)	5 (23.8%) (8.2%, 47.2%)	10 (33.3%) (17.3%, 52.8%)	6 (40.0%) (16.3%, 67.7%)	21 (25.9%) (16.8%, 36.9%)	0.0279*
Anorexia	0 (0.0%) (0.0%, 21.8%)	1 (4.8%) (0.1%, 23.8%)	0 (0%) (0.00%, 11.6%)	0 (0%) (0.00%, 21.8%)	1 (1.2%) (0.0%, 6.7%)	0.6296
Weakness	0	1 (4.8%) (0.1%, 23.8%)	4 (13.3%) (3.8%, 30.7%)	2 (13.3%) (1.7%, 40.5%)	7 (8.6%) (3.6%, 17.0%)	0.4065
Vomiting	0 (0.0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	2 (6.7%) (0.8%, 22.1%)	0 (0.0%) (0.0%, 21.8%)	4 (4.9%) (1.4%, 12.2%)	0.5777
Headache	0 (0.0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	2 (6.7%) (0.8%, 22.1%)	1 (6.7%) (0.2%, 32.0%)	5 (6.2%) (2.0%, 13.8%)	0.8645
Dizziness	0 (0.0%) (0.0%, 21.8%)	0 (0%) (0.00%, 26.1%)	1 (3.33%) (0.1%, 17.2%)	1 (6.67%) (0.2%, 32.0%)	2 (2.5%) (0.3%, 8.6%)	0.8056
Diarrhoea	0 (0.0%) (0.0%, 21.8%)	1 (4.8%) (0.1%, 23.8%)	1 (3.3%) (0.1%, 17.2%)	1 (6.7%) (0.2%, 32.0%)	3 (3.7%) (0.8%, 10.4%)	1.0000
<b>Laboratory results</b>						
Leukocyte count (10 <sup>9</sup> /L)	8.0 ± 2.5	7.8 ± 3.6	8.4 ± 3.5	8.2 ± 4.2	8.1 ± 3.4	0.9337
<10	12 (80.0%) (51.9%, 95.7%)	14 (66.7%) (43.0%, 85.4%)	19 (63.3%) (43.9%, 80.1%)	10 (66.7%) (38.4%, 88.2%)	55 (67.9%) (56.6%, 77.9%)	0.7647
≥10	3 (20.0%) (4.3%, 48.1%)	7 (33.3%) (14.6%, 57.0%)	11 (36.7%) (19.9%, 56.1%)	5 (33.3%) (11.8%, 61.6%)	26 (32.1%) (22.2%, 43.4%)	
Lymphocyte count (10 <sup>9</sup> /L)	1.1 ± 0.3	1.0 ± 0.3	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3	0.8557
<1.0	3 (20.0%) (4.3%, 48.1%)	9 (42.9%) (21.8%, 66.0%)	11 (36.7%) (19.9%, 56.1%)	4 (26.7%) (7.8%, 55.1%)	27 (33.3%) (23.2%, 44.7%)	0.4941
≥1.0	12 (80.0%) (51.9%, 95.7%)	12 (57.1%) (34.0%, 78.2%)	19 (63.3%) (43.9%, 80.1%)	11 (73.3%) (44.9%, 92.2%)	54 (66.7%) (55.3%, 76.8%)	
Platelet count(10 <sup>9</sup> /L)	202.9 ± 67.4	213.5 ± 100.8	206.8 ± 96.1	230.5 ± 134.8	212.2 ± 99.7	0.8723
<100	0 (0.0%) (0.0%, 21.8%)	0 (0.0%) (0.0%, 26.1%)	0 (0.0%) (0.0%, 11.6%)	0 (0.0%) (0.0%, 21.8%)	0 (0.0%) (0.0%, 4.5%)	-
≥100	15 (100%) (78.2%, 100%)	21 (100%) (83.9%, 100%)	30 (100%) (88.4%, 100%)	15 (100%) (78.2%, 100%)	81 (100%) (95.6%, 100%)	
Haemoglobin (ng/mL)	125.1 ± 13.5	126.7 ± 13.4	119.6 ± 12.8	124.8 ± 9.1	123.9 ± 12.0	0.6494
C-reactive protein (mg/L)	6.9 ± 5.4	61.4 ± 39.6	71.3 ± 39.8	49.8 ± 42.4	47.6 ± 41.8	0.0051*
Serum amyloid A protein (mg/L)	143.3 ± 108.4	257.6 ± 264.2	216.6 ± 66.7	/	213.5 ± 177.8	0.3300
ALT (U/L)	30.8 ± 8.9	50.6 ± 24.8	48.7 ± 33.1	50.6 ± 37.7	46.2 ± 29.5	0.1629
AST (U/L)	30.2 ± 8.7	47.7 ± 20.8	42.7 ± 18.0	37.8 ± 16.4	40.8 ± 17.9	0.0026*
≤40	11 (73.3%)	8 (38.1%)	12 (40.0%)	7 (46.7%)	38 (46.9%)	0.1586

	(44.9%, 92.2%)	(18.1%, 61.6%)	(22.7%, 59.4%)	(21.3%, 73.4%)	(35.7%, 58.3%)	
>40	4 (26.7%) (7.8%, 55.1%)	13 (61.9%) (38.4%, 81.9%)	18 (60.0%) (40.6%, 77.3%)	8 (53.3%) (26.6%, 78.7%)	43 (53.1%) (41.7%, 64.3%)	
T-BIL (µmol/L)	9.2 ± 0.6	14.1 ± 4.3	11.9 ± 3.9	/	11.9 ± 3.6	0.4526
Albumin (g/L)	/	34.0 ± 9.3	30.1 ± 2.8	/	32.9 ± 8.1	0.5666
Glucose (mmol/L)	6.4 ± 5.0	5.2 ± 1.9	6.8 ± 1.6	/	6.4 ± 2.1	0.8713
Creatinine (µmol/L)	63.7 ± 16.5	68.0 ± 15.4	115.4 ± 46.2	58.4 ± 1.3	75.4 ± 29.8	0.1803
PT (s)	10.6 ± 0.9	10.5 ± 0.4	10.7 ± 1.0	10.9 ± 1.6	10.7 ± 0.9	0.9022
ATPP (s)	26.9 ± 3.9	34.3 ± 6.7	34.5 ± 13.1	29.2 ± 2.4	32.1 ± 7.6	0.4814
TT (s)	21.8 ± 5.4	32.3 ± 8.2	24.9 ± 7.6	32.3 ± 7.9	28.9 ± 8.4	0.3169
FIB (g/L)	0.7 ± 0.3	1.92 ± 3.5	2.3 ± 3.0	0.3 ± 0.1	1.5 ± 2.3	0.7960
D-dimer (mg/L)	6.5 ± 0.3	6.9 ± 1.1	5.8 ± 0.2	/	6.5 ± 0.8	0.4940
<b>Comorbidities, n (%)</b>	4 (26.7%) (7.8%, 55.1%)	5 (23.8%) (8.2%, 47.2%)	9 (30.0%) (14.7%, 49.4%)	3 (20.0%) (4.3%, 48.1%)	21 (25.9%) (16.8%, 36.9%)	0.9397
Chronic pulmonary disease	1 (6.7%) (0.2%, 32.0%)	3 (14.3%) (3.1%, 36.3%)	3 (10.0%) (2.1%, 26.5%)	2 (13.3%) (1.7%, 40.5%)	9 (11.1%) (5.2%, 20.1%)	0.8945
Diabetes	3 (20.0%) (4.3%, 48.1%)	2 (9.5%) (1.2%, 30.4%)	3 (10.0%) (2.1%, 26.5%)	2 (13.3%) (1.7%, 40.5%)	10 (12.4%) (6.1%, 21.5%)	0.8005
Hypertension	2 (13.3%) (1.7%, 40.5%)	1 (4.8%) (0.1%, 23.8%)	7 (23.3%) (9.9%, 42.3%)	2 (13.3%) (1.7%, 40.5%)	12 (14.8%) (7.9%, 24.5%)	0.3571
Chronic renal function failure	0 (0.0%) (0.0%, 21.8%)	0 (0.0%) (0.0%, 26.1%)	3 (10.0%) (2.1%, 26.5%)	0 (0.0%) (0.0%, 21.8%)	3 (3.7%) (0.8%, 10.4%)	0.3101
Cardiovascular disease	3 (20.0%) (4.3%, 48.1%)	1 (4.8%) (0.1%, 23.8%)	3 (10.0%) (2.1%, 26.5%)	1 (6.7%) (0.5%, 32.0%)	8 (9.9%) (4.4%, 18.5%)	0.5494
Cerebrovascular disease	1 (6.7%) (0.2%, 32.0%)	1 (4.8%) (0.1%, 23.8%)	3 (10.0%) (2.1%, 26.5%)	1 (6.7%) (0.2%, 32.0%)	6 (7.4%) (2.8%, 15.4%)	0.9367
Malignancy	1 (6.7%) (0.2%, 32.0%)	1 (4.8%) (0.1%, 23.8%)	2 (6.7%) (0.8%, 22.1%)	0 (0.0%) (0.0%, 21.8%)	4 (5.0%) (1.4%, 12.2%)	0.9148
Hepatitis or liver cirrhosis	0 (0.0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	3 (10.0%) (2.1%, 26.5%)	2 (13.3%) (1.7%, 40.5%)	7 (8.6%) (3.6%, 17.0%)	0.6812

Numerical data are mean ± SD; nominal data are n (%) (95% CI).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-BIL, total bilirubin; PT, prothrombin time; APTT, Activated partial thromboplastin time; TT, thrombin time; FIB, fibrinogen

\*p<0.05 between groups 1–4

**Table 2. Imaging features extracted from CT images of patients with COVID-19 pneumonia**

<b>CT characteristics</b>	<b>Definition</b>
Lung involvement	Categorized as unilateral or bilateral lung involvement
The lung segment involved	Each segment of the lung was reviewed for presence of any opacification
Location	Central, lesion located in the interior two-thirds of the lung; Peripheral, in the outer one-third of the lung; Both central and peripheral
Predominant distribution of opacities	Subpleural, involving mainly the peripheral of the lung; Peribronchovascular, surrounding mainly the peribronchovascular bundle. Random, without predilection for subpleural or peribronchovascular regions
Extent of lesion involvement	Categorized as focal, multifocal, diffuse
Predominantly CT pattern	Ground glass opacity pattern, a hazy, gauze-like opacity, through which pulmonary vessels are still visible; Consolidation pattern, homogeneous opacification of the parenchyma with obscuration of the underlying vessels; Reticular pattern, interstitial lesions of pulmonary parenchymal; Mixed pattern, combination of consolidation, ground glass opacities, and reticular opacities
Presence of nodule	Categorized as random, centrilobular, subpleural, peribronchovascular
Tree-in-bud	Constellation of small centrilobular nodule and concomitant branching opacities
Margin definition	Evaluated in the lung window, and indicated as well-defined, or poor-defined
Interlobular septal thickening	Categorized as smooth interlobular septal thickening or irregular interlobular septal thickening
Presence of crazy-paving	Interlobular septal thickening with superimposed ground glass opacification
Presence of air bronchogram	A pattern of air-filled (low-attenuation) bronchi on a back- ground of opaque (high-attenuation) air- less lung
Bronchiolectasis	Dilatation of bronchioles
Cavitation	Presence or absence of cavitation
Calcifications	Presence or absence of calcifications
Round cystic changes	Presence or absence of round cystic changes
Thickening of the adjacent pleura	Thickening of the adjacent fissural or peripheral pleura
Pleural effusion	Fluid in the pleural cavity
Lymphadenopathy	Presence or absence of thoracic lymphadenopathy (hilar or mediastinal) with short-axis diameter greater than 1 cm
Evolution of areas of opacification on follow-up chest CT	Categorized as no significant change, resolution or develop

**Table 3. CT Features of Patients with COVID-19 pneumonia**

<b>Location</b>	<b>Group 1 (n=15)</b>	<b>Group 2 (n=21)</b>	<b>Group 3 (n=30)</b>	<b>Group 4 (n=15)</b>	<b>All patients (n=81)</b>	<b>p value</b>
<b>Lung involvement</b>						
Unilateral	9 (60.0%) (32.3%, 83.7%)	2 (9.5%) (1.2%, 30.4%)	4 (13.3%) (3.8%, 30.7%)	2 (13.3%) (1.7%, 40.5%)	17 (21.0%) (12.7%, 31.5%)	0.0019*
Bilateral	6 (40.0%) (16.3%, 67.7%)	19 (90.5%) (69.6%, 98.8%)	26 (86.7%) (69.3%, 96.2%)	13 (86.7%) (59.5%, 98.3%)	64 (79.0%) (68.5%, 87.3%)	
<b>Location</b>						
Central	6 (40.0%) (16.3%, 67.7%)	2 (9.5%) (1.2%, 30.4%)	2 (6.7%) (0.8%, 22.1%)	0 (0.0%) (0.0%, 21.8%)	10 (12.4%) (6.1%, 21.5%)	0.0002*
Peripheral	9 (60.0%) (32.3%, 83.7%)	15 (71.4%) (47.8%, 88.7%)	12 (40.0%) (22.7%, 59.4%)	8 (53.3%) (26.6%, 78.7%)	44 (54.3%) (42.9%, 65.4%)	
Both central and peripheral	0 (0.0%) (0.0%, 21.8%)	4 (19.1%) (5.5%, 41.9%)	16 (53.3%) (34.3%, 71.7%)	7 (46.7%) (21.3%, 73.4%)	27 (33.3%) (23.2%, 44.7%)	
<b>Predominant distribution of opacities</b>						
Random	2 (13.3%) (1.7%, 40.5%)	10 (47.6%) (25.7%, 70.2%)	15 (50.0%) (31.3%, 68.7%)	6 (40.0%) (16.3%, 67.7%)	33 (40.7%) (30.0%, 52.2%)	0.1166
Subpleural	9 (60.0%) (32.3%, 83.7%)	6 (28.6%) (11.3%, 52.2%)	13 (43.3%) (25.5%, 62.6%)	7 (46.7%) (21.3%, 73.4%)	35 (43.2%) (32.2%, 54.7%)	
Peribronchovascular	4 (26.7%) (7.8%, 55.1%)	5 (23.8%) (8.2%, 47.2%)	2 (6.7%) (0.8%, 22.1%)	2 (13.3%) (1.7%, 40.5%)	13 (16.1%) (8.8%, 25.9%)	
<b>Extent of lesion involvement</b>						
focal	7 (46.7%) (21.3%, 73.4%)	5 (23.8%) (8.2%, 47.2%)	3 (10.0%) (2.1%, 26.5%)	0 (0.0%) (0.0%, 21.8%)	15 (18.5%) (10.8%, 28.7%)	0.0001*
multifocal	8 (53.3%) (26.6%, 78.7%)	5 (23.8%) (8.2%, 47.2%)	9 (30.0%) (14.7%, 49.4%)	8 (53.3%) (26.6%, 78.7%)	30 (37.0%) (26.6%, 48.5%)	
diffuse	0 (0.0%) (0.0%, 21.8%)	11 (52.4%) (29.8%, 74.3%)	18 (60.0%) (40.6%, 77.3%)	7 (46.7%) (21.3%, 73.4%)	36 (44.4%) (33.4%, 55.9%)	
<b>Predominant CT pattern</b>						
Ground glass opacity pattern	14 (93.3%) (68.1%, 99.8%)	17 (81.0%) (58.1%, 94.6%)	17 (56.7%) (37.4%, 74.5%)	5 (33.3%) (11.8%, 61.6%)	53 (65.4%) (54.0%, 75.7%)	0.0046*
Consolidation pattern	1 (6.7%) (0.2%, 32.0%)	1 (4.8%) (0.1%, 23.8%)	9 (30.0%) (14.7%, 49.4%)	3 (20.0%) (4.3%, 48.1%)	14 (17.3%) (9.8%, 27.3%)	
Reticular pattern	0 (0.0%) (0.0%, 21.8%)	0 (0.0%) (0.0%, 16.1%)	1 (3.3%) (0.1%, 17.2%)	2 (13.3%) (1.7%, 40.5%)	3 (3.7%) (0.8%, 10.4%)	

Mixed pattern	0 (0.0%) (0.0%, 21.8%)	3 (14.3%) (3.1%, 36.3%)	3 (10.0%) (2.1%, 26.5%)	5 (33.3%) (11.8%, 61.6%)	11 (13.6%) (7.0%, 23.0%)	
Presence of nodule	0 (0.0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	3 (10.0%) (2.1%, 26.5%)	0 (0.0%) (0.0%, 21.8%)	5 (6.2%) (2.0%, 13.8%)	0.4697
<b>Margin definition</b>						
Well-defined	3 (20.0%) (4.3%, 48.1%)	5 (23.8%) (8.2%, 47.5%)	6 (20.0%) (7.7%, 38.6%)	1 (6.7%) (0.2%, 32.0%)	15 (18.5%) (10.8%, 28.7%)	0.6397
Ill-defined	12 (80.0%) (51.9%, 95.7%)	16 (76.2%) (52.8%, 91.8%)	24 (80.0%) (61.4%, 92.3%)	14 (93.3%) (68.1%, 99.8%)	66 (81.5%) (71.3%, 89.3%)	
<b>Interlobular septal thickening</b>						
Absence	15 (100%) (78.2%, 100%)	11 (52.4%) (29.8%, 74.3%)	17 (56.7%) (37.4%, 74.5%)	10 (66.7%) (38.4%, 88.2%)	53 (65.4%) (54.0%, 75.7%)	0.0030*
Smooth	0 (0.0%) (0.0%, 21.8%)	9 (42.9%) (21.8%, 66.0%)	8 (26.7%) (12.1%, 45.9%)	1 (6.7%) (0.2%, 32.0%)	18 (22.2%) (13.7%, 32.8%)	
Irregular	0 (0.0%) (0.0%, 21.8%)	1 (4.8%) (0.1%, 23.8%)	5 (16.7%) (5.6%, 34.7%)	4 (26.7%) (7.8%, 55.1%)	10 (12.4%) (6.1%, 21.5%)	
Bronchiolectasis	0 (100%) (0.0%, 21.8%)	3 (14.3%) (3.1%, 36.3%)	4 (13.3%) (3.8%, 30.7%)	2 (13.3%) (1.7%, 40.5%)	9 (11.1%) (5.2%, 20.1%)	0.4651
Crazy-paving	0 (0.0%) (0.0%, 21.8%)	2 (9.5%) (1.2%, 30.4%)	4 (13.3%) (3.8%, 30.7%)	2 (13.3%) (1.7%, 40.5%)	8 (9.9%) (4.4%, 18.5%)	0.6052
Air bronchogram	1 (6.7%) (0.2%, 32.0%)	12 (57.1%) (34.0%, 78.2%)	18 (60.0%) (40.6%, 77.3%)	7 (46.7%) (21.3%, 73.4%)	38 (46.9%) (35.7%, 58.3%)	0.0033*
Round cystic changes	0 (0.0%) (0.0%, 21.8%)	3 (14.3%) (3.1%, 36.3%)	4 (13.3%) (3.8%, 30.7%)	1 (6.7%) (0.2%, 32.0%)	8 (9.9%) (4.4%, 18.5%)	0.4780
Thickening of the adjacent pleura	0 (0.0%) (0.0%, 21.8%)	5 (23.8%) (8.2%, 47.2%)	14 (46.7%) (28.3%, 65.7%)	7 (46.7%) (21.3%, 73.4%)	26 (32.1%) (22.2%, 43.4%)	0.0029*
Pleural effusion	0 (0.0%) (0.0%, 21.8%)	1 (4.8%) (0.12%, 23.8%)	1 (3.3%) (0.1%, 17.2%)	2 (13.3%) (1.7%, 40.5%)	4 (4.9%) (1.4%, 12.2%)	0.4715
Lymphadenopathy	0 (0.0%) (0.0%, 21.8%)	3 (14.3%) (3.1%, 36.3%)	0 (0%) (0.088.4%, 11.6%)	2 (13.3%) (1.7%, 40.5%)	5 (6.2%) (2.0%, 13.8%)	0.0372*

Data are n (%) (95% CI).

\*p<0.05 between groups 1–4.

**Table 4 Number of segments affected by lesions between groups**

Location	Group 1 (n=15)	Group 2 (n=21)	Group 3 (n=30)	Group 4 (n=15)	All patients (n=81)	p value
<b>Left upper lobe</b>						
Apical posterior	0 (0.0%) (0.0%, 21.8%)	7 (33.3%) (14.6%, 57.0%)	17 (56.7%) (37.4%, 74.5%)	9 (60.0%) (32.3%, 83.7%)	33 (40.7%) (30.0%, 52.2%)	0.0003*
Anterior	3 (20.0%) (4.3%, 48.1%)	13 (61.9%) (38.4%, 81.9%)	25 (83.3%) (65.3%, 94.4%)	10 (66.7%) (38.4%, 88.2%)	51 (63.0%) (51.5%, 73.4%)	0.0005*
Superior lingula	1 (6.7%) (0.2%, 32.0%)	14 (66.7%) (43.0%, 85.4%)	21 (70.0%) (50.6%, 85.3%)	11 (73.3%) (44.9%, 92.2%)	47 (58.0%) (46.5%, 68.9%)	0.0001*
Inferior lingula	1 (6.7%) (0.2%, 32.0%)	13 (61.9%) (38.4%, 81.9%)	19 (63.3%) (43.9%, 80.1%)	9 (60.0%) (32.3%, 83.7%)	42 (51.9%) (40.5%, 63.1%)	0.0010*
Total	5	47	82	39	173	
<b>Left lower lobe</b>						
Superior	7 (46.7%) (21.3%, 73.4%)	19 (90.5%) (69.6%, 98.8%)	25 (83.3%) (65.3%, 94.4%)	12 (80.0%) (51.9%, 95.7%)	63 (77.8%) (67.2%, 86.3%)	0.0207*
Medial Anterior basal	2 (13.3%) (1.7%, 40.5%)	8 (38.1%) (18.1%, 61.6%)	18 (60.0%) (40.6%, 77.3%)	7 (46.7%) (21.3%, 73.4%)	35 (43.2%) (32.2%, 54.7%)	0.0222*
Lateral basal	4 (26.7%) (7.8%, 55.1%)	14 (66.7%) (43.0%, 85.4%)	22 (73.3%) (54.1%, 87.7%)	9 (60.0%) (32.3%, 83.7%)	49 (60.5%) (49.0%, 71.2%)	0.0254*
Posterior	2 (13.3%) (1.7%, 40.5%)	16 (76.2%) (52.8%, 91.8%)	24 (80.0%) (61.4%, 92.3%)	13 (86.7%) (59.5%, 98.3%)	55 (67.9%) (56.6%, 77.9%)	<0.0001*
Total	15	57	89	41	202	
<b>Right upper lobe</b>						
Apical	4 (26.7%) (7.8%, 55.1%)	15 (71.4%) (47.8%, 88.7%)	24 (80.0%) (61.4%, 92.3%)	12 (80.0%) (51.9%, 95.7%)	55 (67.9%) (56.6%, 77.9%)	0.0031*
Posterior	4 (26.7%) (7.8%, 55.1%)	13 (61.9%) (38.4%, 81.9%)	26 (86.7%) (69.3%, 96.2%)	10 (66.7%) (38.4%, 88.2%)	53 (65.4%) (54.0%, 75.7%)	0.0010*
Anterior	1 (6.7%) (0.2%, 32.0%)	16 (76.2%) (52.8%, 91.8%)	25 (83.3%) (65.3%, 94.4%)	11 (73.3%) (44.9%, 92.2%)	53 (65.4%) (54.0%, 75.7%)	<0.0001*
Total	9	44	75	33	161	
<b>Right middle lobe</b>						
Lateral	0 (0.0%) (0.0%, 21.8%)	15 (71.4%) (47.8%, 88.7%)	21 (70.0%) (50.6%, 85.3%)	12 (80.0%) (51.9%, 95.7%)	48 (59.3%) (47.8%, 70.1%)	<0.0001*
Medial	1 (6.7%) (0.2%, 32.0%)	10 (47.6%) (25.7%, 70.2%)	20 (66.7%) (47.2%, 82.7%)	8 (53.3%) (26.6%, 78.7%)	39 (48.2%) (36.9%, 59.5%)	0.0013*



Total	2	25	41	20	87	
<b>Right lower lobe</b>						
Superior	4 (26.7%) (7.8%, 55.1%)	16 (76.2%) (52.8%, 91.8%)	23 (76.7%) (57.7%, 90.1%)	12 (80.0%) (51.9%, 95.7%)	55 (67.9%) (56.6%, 77.9%)	0.0040*
Medial basal	3 (20.0%) (4.3%, 48.1%)	9 (42.9%) (21.8%, 66.0%)	19 (63.3%) (43.9%, 80.1%)	9 (60.0%) (32.3%, 83.7%)	40 (49.4%) (38.1%, 60.7%)	0.0347*
Anterior	1 (6.7%) (0.2%, 32.0%)	10 (47.6%) (25.7%, 70.2%)	15 (50.0%) (31.3%, 68.7%)	7 (46.7%) (21.3%, 73.4%)	33 (40.7%) (30.0%, 52.2%)	0.0197*
Lateral basal	1 (6.7%) (0.2%, 32.0%)	12 (57.1%) (34.0%, 78.2%)	21 (70.0%) (50.6%, 85.3%)	10 (66.7%) (38.4%, 88.2%)	44 (54.3%) (42.9%, 65.4%)	0.0003*
Posterior	4 (26.7%) (7.8%, 55.1%)	14 (66.7%) (43.0%, 85.4%)	24 (80.0%) (61.4%, 92.3%)	11 (73.3%) (45.0%, 92.2%)	53 (65.4%) (54.0%, 75.7%)	0.0057*
Total	13	61	102	49	225	
<b>Total of all segments involved</b>	44	234	389	182	849	
<b>Average segments involved</b>	2.8 ± 3.3	11.1 ± 5.4	13.0 ± 5.7	12.1 ± 5.9	10.5 ± 6.4	<0.0001*

Data are n (%) (95% CI).

\*p<0.05 between groups 1–4.